SyntekaBio Balance Sheet Health
Financial Health criteria checks 4/6
SyntekaBio has a total shareholder equity of ₩31.6B and total debt of ₩6.9B, which brings its debt-to-equity ratio to 21.8%. Its total assets and total liabilities are ₩53.0B and ₩21.4B respectively.
Key information
21.8%
Debt to equity ratio
₩6.89b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩19.75b |
| Equity | ₩31.63b |
| Total liabilities | ₩21.40b |
| Total assets | ₩53.03b |
Financial Position Analysis
Short Term Liabilities: A226330's short term assets (₩20.8B) exceed its short term liabilities (₩19.0B).
Long Term Liabilities: A226330's short term assets (₩20.8B) exceed its long term liabilities (₩2.4B).
Debt to Equity History and Analysis
Debt Level: A226330 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A226330's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A226330 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A226330 has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 22% each year.